{
    "name": "tolcapone",
    "comment": "Rx",
    "other_names": [
        "Tasmar"
    ],
    "classes": [
        "Antiparkinson Agents",
        "COMT Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/tasmar-tolcapone-343053",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: not known if secreted in breast milk, use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: not known if secreted in breast milk, use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Because of risk of potentially fatal, acute fulminant liver failure, reserve use for in patients with Parkinsonâ€™s disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies",
                "If substantial benefit not observed within 3 weeks following initiation, withdraw therapy",
                "Do not initiate if clinical evidence of liver disease or two SGPT/ALT or SGOT/AST values >ULN",
                "Discontinue if SGPT/ALT or SGOT/AST levels exceed 2 xULN or if clinical signs and symptoms suggest the onset of hepatic dysfunction (persistent nausea, fatigue, lethargy, anorexia, jaundice, dark urine, pruritus, and right upper quadrant tenderness)",
                "Patients with severe dyskinesia or dystonia should be treated with caution",
                "Patients who develop hepatocellular injury while taking tolcapone and are withdrawn from the drug are at increased risk for liver injury if tolcapone reintroduced"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Liver disease or history of tolcapone-induced hepatotoxicity",
                "History of: non-traumatic rhabdomyolysis, drug-related hyperpyrexia & confusion"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Risk of potentially fatal hepatotoxicity; withdraw drug if no improvement in 3 wk",
                "Do not initiate treatment if AST/ALT >ULN; discontinue if liver enzymes >2 xULN",
                "Impulse control/compulsive behaviors: Risk of uncontrollable sexual, gambling or other urges",
                "Orthostatic hypotension, diarrhea, hallucinations, psychotic-like behavior, rhabdomyolysis, renal/hepatic impairment, hematuria, hyperpyrexia, confusion, and fibrotic complications may occur",
                "May be linked to higher melanoma risk in Parkinson's patients",
                "Avoid abrupt withdrawal",
                "May increase risk for falling asleep during activities of daily living",
                "Do not coadminister with nonselective MAO inhibitor (ie, MAO-A inhibitors); combination may result in result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism",
                "Discontinued in Canada"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "tolcapone, isocarboxazid.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and tolcapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenelzine",
            "description": {
                "common": "tolcapone, phenelzine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and tolcapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tolcapone, tranylcypromine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and tolcapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "tolcapone, metoclopramide intranasal.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "tolcapone and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b and tolcapone both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acrivastine",
            "description": {
                "common": "acrivastine and tolcapone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and tolcapone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and tolcapone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and tolcapone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "avapritinib and tolcapone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen and tolcapone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "brexpiprazole and tolcapone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "tolcapone and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and tolcapone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dobutamine",
            "description": {
                "common": "tolcapone will increase the level or effect of dobutamine by  decreasing metabolism. Use Caution/Monitor. Tolcapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dopamine",
            "description": {
                "common": "tolcapone will increase the level or effect of dopamine by  decreasing metabolism. Use Caution/Monitor. Tolcapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine",
            "description": {
                "common": "tolcapone will increase the level or effect of epinephrine by  decreasing metabolism. Use Caution/Monitor. Tolcapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine inhaled",
            "description": {
                "common": "tolcapone will increase the level or effect of epinephrine inhaled by  decreasing metabolism. Use Caution/Monitor. Tolcapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine racemic",
            "description": {
                "common": "tolcapone will increase the level or effect of epinephrine racemic by  decreasing metabolism. Use Caution/Monitor. Tolcapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "tolcapone and ganaxolone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoproterenol",
            "description": {
                "common": "tolcapone will increase the level or effect of isoproterenol by  decreasing metabolism. Use Caution/Monitor. Tolcapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyldopa",
            "description": {
                "common": "tolcapone will increase the level or effect of methyldopa by  decreasing metabolism. Use Caution/Monitor. Tolcapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "norepinephrine",
            "description": {
                "common": "tolcapone will increase the level or effect of norepinephrine by  decreasing metabolism. Use Caution/Monitor. Tolcapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Dyskinesia",
            "percent": "45-50"
        },
        {
            "name": "Nausea",
            "percent": "30-35"
        },
        {
            "name": "Insomnia",
            "percent": "21-25"
        },
        {
            "name": "Hallucinations",
            "percent": "8-24"
        },
        {
            "name": "Excessive dreaming",
            "percent": "16-21"
        },
        {
            "name": "Diarrhea",
            "percent": "16-20"
        },
        {
            "name": "Anorexia",
            "percent": "16-20"
        },
        {
            "name": "Dystonia",
            "percent": "16-20"
        },
        {
            "name": "Muscle cramping",
            "percent": "16-20"
        },
        {
            "name": "Somnolence",
            "percent": "16-20"
        },
        {
            "name": "Orthostatic hypotension",
            "percent": "11-15"
        },
        {
            "name": "Confusion",
            "percent": "10-11"
        },
        {
            "name": "Headache",
            "percent": "10-11"
        },
        {
            "name": "Vomiting",
            "percent": "8-10"
        },
        {
            "name": "Constipation",
            "percent": "6-8"
        },
        {
            "name": "URI",
            "percent": "5-7"
        },
        {
            "name": "Fatigue",
            "percent": "3-7"
        },
        {
            "name": "Abdominal pain",
            "percent": "5-6"
        },
        {
            "name": "Xerostomia",
            "percent": "5-6"
        },
        {
            "name": "UTI",
            "percent": "5"
        },
        {
            "name": "Hematuria",
            "percent": "4-5"
        },
        {
            "name": "Syncope",
            "percent": "4-5"
        },
        {
            "name": "Dyspnea",
            "percent": "3"
        },
        {
            "name": "Loss of balance",
            "percent": "2-3"
        },
        {
            "name": "Urine discoloration",
            "percent": "2-3"
        },
        {
            "name": "Chest pain",
            "percent": "1-3"
        },
        {
            "name": "Hyper",
            "percent": "1-3"
        },
        {
            "name": "hypokinesia",
            "percent": "1-3"
        },
        {
            "name": "Parasthesia",
            "percent": "1-3"
        },
        {
            "name": "Transaminases increased",
            "percent": "3"
        },
        {
            "name": "usually",
            "percent": "6"
        },
        {
            "name": "x ULN in first",
            "percent": "2"
        },
        {
            "name": "mos of therapy",
            "percent": "2"
        },
        {
            "name": "Hypotension",
            "percent": "2"
        },
        {
            "name": "Neck pain",
            "percent": "1-2"
        },
        {
            "name": "Stiffness",
            "percent": null
        },
        {
            "name": "Sinus congestion",
            "percent": null
        },
        {
            "name": "Dysphagia",
            "percent": null
        },
        {
            "name": "GI hemorrhage",
            "percent": null
        },
        {
            "name": "Gastroenteritis",
            "percent": null
        },
        {
            "name": "Mouth ulceration",
            "percent": null
        },
        {
            "name": "Salivation increase",
            "percent": null
        },
        {
            "name": "Esophagitis",
            "percent": null
        },
        {
            "name": "Cholelithiasis",
            "percent": null
        },
        {
            "name": "Colitis",
            "percent": null
        },
        {
            "name": "Dopaminergic side effects due to increased dopamine levels",
            "percent": null
        },
        {
            "name": "Hepatocellular injury",
            "percent": null
        },
        {
            "name": "including liver failure",
            "percent": null
        }
    ]
}